Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors
Author:
Affiliation:
1. Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City
Publisher
American Medical Association (AMA)
Subject
General Medicine
Link
https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2779689/zhou_2021_ld_210060_1619722926.35343.pdf
Reference6 articles.
1. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.;Cerami;Cancer Discov,2012
2. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.;Samstein;Nat Genet,2019
3. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.;Domchek;Lancet Oncol,2020
4. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer.;Vinayak;JAMA Oncol,2019
5. A C-X-C chemokine receptor type 2-dominated cross-talk between tumor cells and macrophages drives gastric cancer metastasis.;Zhou;Clin Cancer Res,2019
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Complete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report;Oral Oncology;2023-12
2. Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor;Japanese Journal of Clinical Oncology;2023-11-11
3. Emerging Prognostic and Predictive Factors in Pancreatic Cancer;Modern Pathology;2023-11
4. Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities;Critical Reviews in Oncology/Hematology;2023-10
5. Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma;Cancer Biology & Therapy;2023-09-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3